BACKGROUND: A growing body of evidence suggests that repetitive transcranial magnetic stimulation (rTMS) can alleviate negative and positive symptoms of refractory schizophrenia. However, trials to date have been small and results are mixed. METHODS: We performed meta-analyses of all prospective studies of the therapeutic application of rTMS in refractory schizophrenia assessing the effects of high-frequency rTMS to the left dorsolateral prefrontal cortex (DLPFC) to treat negative symptoms, and low-frequency rTMS to the left temporo-parietal cortex (TPC) to treat auditory hallucinations (AH) and overall positive symptoms. RESULTS: When analyzing controlled (active arms) and uncontrolled studies together, the effect sizes showed significant and moderate effects of rTMS on negative and positive symptoms (based on PANSS-N or SANS, and PANSS-P or SAPS, respectively). However, the analysis for the sham-controlled studies revealed a small non-significant effect size for negative (0.27, p=0.417) and for positive symptoms (0.17, p=0.129). When specifically analyzing AH (based on AHRS, HCS or SAH), the effect size for the sham-controlled studies was large and significant (1.04; p=0.002). CONCLUSIONS: These meta-analyses support the need for further controlled, larger trials to assess the clinical efficacy of rTMS on negative and positive symptoms of schizophrenia, while suggesting the need for exploration for alternative stimulation protocols.
BACKGROUND: A growing body of evidence suggests that repetitive transcranial magnetic stimulation (rTMS) can alleviate negative and positive symptoms of refractory schizophrenia. However, trials to date have been small and results are mixed. METHODS: We performed meta-analyses of all prospective studies of the therapeutic application of rTMS in refractory schizophrenia assessing the effects of high-frequency rTMS to the left dorsolateral prefrontal cortex (DLPFC) to treat negative symptoms, and low-frequency rTMS to the left temporo-parietal cortex (TPC) to treat auditory hallucinations (AH) and overall positive symptoms. RESULTS: When analyzing controlled (active arms) and uncontrolled studies together, the effect sizes showed significant and moderate effects of rTMS on negative and positive symptoms (based on PANSS-N or SANS, and PANSS-P or SAPS, respectively). However, the analysis for the sham-controlled studies revealed a small non-significant effect size for negative (0.27, p=0.417) and for positive symptoms (0.17, p=0.129). When specifically analyzing AH (based on AHRS, HCS or SAH), the effect size for the sham-controlled studies was large and significant (1.04; p=0.002). CONCLUSIONS: These meta-analyses support the need for further controlled, larger trials to assess the clinical efficacy of rTMS on negative and positive symptoms of schizophrenia, while suggesting the need for exploration for alternative stimulation protocols.
Authors: Ghassen Saba; Jean François Rocamora; Khalid Kalalou; René Benadhira; Marion Plaze; Béatrice Aubriot-Delmas; Dominique Januel Journal: Am J Psychiatry Date: 2002-10 Impact factor: 18.112
Authors: Matti M Holi; Markku Eronen; Kari Toivonen; Päivi Toivonen; Mauri Marttunen; Hannu Naukkarinen Journal: Schizophr Bull Date: 2004 Impact factor: 9.306
Authors: Andrew M McIntosh; David Semple; Katherine Tasker; Lesley K Harrison; David G C Owens; Eve C Johnstone; Klaus P Ebmeier Journal: Psychiatry Res Date: 2004-06-30 Impact factor: 3.222
Authors: Ralph E Hoffman; Keith A Hawkins; Ralitza Gueorguieva; Nash N Boutros; Fady Rachid; Kathleen Carroll; John H Krystal Journal: Arch Gen Psychiatry Date: 2003-01
Authors: Iris E C Sommer; Christina W Slotema; Zafiris J Daskalakis; Eske M Derks; Jan Dirk Blom; Mark van der Gaag Journal: Schizophr Bull Date: 2012-02-24 Impact factor: 9.306